… These beneficial effects of dapagliflozin in heart failure with reduced ejection … dapagliflozin
or placebo. One patient in each of the dapagliflozin and placebo groups died during the study…

… (with and without atherosclerotic cardiovascular disease), heart failure and chronic
kidney disease, and may provide similar organ protection in high-risk patients with COVID-19. …

… We hypothesized that dapagliflozin, as a new star in the treatment of heart failure, could
improve sleep apnea in heart failure patients. In our study, patients with heart failure complicated …

… In addition, several studies have also reported improved diastolic function in animals and …
therefore studied the effects of the GLP-1 RA liraglutide (Lira) and the SGLT2i dapagliflozin (…

… that dapagliflozin provided similar value across heart failure … health status impairment due
to heart failure, the cost per QALY … evaluation study demonstrates that dapagliflozin provides …

… Among the 234 participants included in the current study (Table 1), 121 were randomized
to dapagliflozin and 113 to placebo. The average age was 62±11 years, 25% were women, …

… occurring in the same time window between 2 study visits, the beneficial effect of
dapagliflozin in comparison with placebo was not modified with a HR of 0.71 (95% CI, 0.60–0.85). …

… In this research, we observed that dapagliflozin can reduce pulmonary vascular damage
and RHD in MCT-exposed rats. In addition, it can also reduce the susceptibility to AF caused by …

… Failure) trial, we evaluated the effect of the SGLT2 inhibitor, dapagliflozin, versus placebo,
according to a modified Heart … With respect to safety and tolerability, study drug …

… DELIVER phase 3 trial. “Earlier heart failure with preserved ejection fraction trials have shown
… in the highest left ventricular ejection fraction but with dapagliflozin results are consistent …